Pharmeasy’s Valuation Slashed By 90% By Investor Neuberger Berman

Pharmeasy’s Valuation Slashed By 90% By Investor Neuberger Berman.

Expert Analysis:

• The valuation was reduced by 90%, and shares Neuberger Berman acquired for $8.87 million in October 2021 are now valued at just $823,432.

• In July 2023 was seeking emergency funds at a valuation of $500-600 million.

• Over eight years, PharmEasy raised $1.6 billion but eroded nearly Rs. 8,000 crore.

• PharmEasy acquired Thyrocare for Rs. 4,500 crore, financed by a 5-year loan from Kotak Mahindra Bank. Later, it took a Rs. 2,280 crore loan from Goldman Sachs to repay the Kotak loan.